Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

CANADA: 2 Doses of HPV Vaccine in Girls May Offer Similar Protection as 3 Doses in Young Women


Infection Control Today (04.30.2013) Aids Weekly Plus

Results of a recent study by Simon R.M. Dobson, MD, and colleagues at the University of British Columbia in Vancouver, Canada, indicated that girls who received two doses of human papillomavirus (HPV) vaccine had immune responses to HPV-16 and HPV-18 infection noninferior to those of young women who received the usual three doses of the vaccine. They also examined antibody levels to two other strains of the virus, HPV-6 and HPV-11 and compared girls given two or three doses. The researchers conducted the randomized, phase 3, multicenter study of 830 Canadian females from August 2007 through February 2011. Researchers also collected blood samples from 675 participants (81 percent) for follow up. The 261 girls ages 9–13 years received three doses of quadrivalent HPV vaccine at 0, 2, and 6 months; and 259 girls received two doses at 0 and 6 months. The 310 young women ages 16–26 years received three doses of vaccine at 0, 2, and 6 months. Researchers measured antibody levels at 0, 7, 18, 24, and 36 months. Antibody levels in girls given two doses were noninferior to those of women given three doses for all four HPV genotypes. Girls given two doses versus three doses had noninferior antibody response for all four vaccines. The antibody levels for girls given two doses compared to women given three doses remained noninferior for all genotypes for 36 months. However, antibody responses in girls given two doses compared to those of girls given three doses for all four vaccine genotypes were noninferior at month 7, but not for HPV-18 by month 24, or HPV-6 by month 36. The authors note that more data on the length of protection are needed before they can recommend reduced dose schedules of the vaccine. The full report, “Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women: A Randomized Clinical Trial,” was published in the journal JAMA (2013; 309(17):1793–1802).


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

Information in this article was accurate in May 1, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.